You have been successfully logged out.
Yescarta®▼ (axicabtagene ciloleucel)
Yescarta® is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Yescarta® is indicated for the treatment of adult patients with relapsed or refractory (R/R) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
Explore clinical efficacy and safety data in:
DLBCL second-line or more
Tecartus®▼ (brexucabtagene autoleucel)
Tecartus® has been granted conditional marketing authorisation and is indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.
Tecartus® is additionally indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (ALL).
Explore clinical efficacy and safety data in:
MCL ALLApril 2025 UKI-YES-0065
Adverse events should be reported.
For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). For IE, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to [email protected] or +44(0) 1223 897500 or +353(0) 21 482 5999.